Trials / Completed
CompletedNCT03239691
A Study to Evaluate the Effect of ACT-709478 in Photosensitive Epilepsy Patients
A Phase 2a, Multi-center, Single-blind, Within-subject, Placebo-controlled Study to Assess the Pharmacodynamics of ACT-709478 in Subjects With Photosensitive Epilepsy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Idorsia Pharmaceuticals Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The main study objective is to assess the effect of ACT-709478 in male and female subjects with photosensitive epilepsy following single dose administration
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ACT-709478 for oral use | Hard gelatin capsules for oral administration formulated at strengths of 10 mg and 100 mg |
| DRUG | Placebo | Matching placebo available as matching capsules for oral administration |
Timeline
- Start date
- 2017-10-06
- Primary completion
- 2018-04-25
- Completion
- 2018-04-25
- First posted
- 2017-08-04
- Last updated
- 2018-08-31
Locations
5 sites across 2 countries: France, Germany
Source: ClinicalTrials.gov record NCT03239691. Inclusion in this directory is not an endorsement.